Clinical Trial Update: Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a combination of selumetinib, a bromodomain inhibitor, and durvalumab for sarcomas, with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Peripheral Nerve Sheath Tumor
• Neurofibromatosis Type
• Sarcoma

Drugs mentioned

• Bromodomain inhibitor (unspecified)
• Durvalumab (durvalumab)
• Selumetinib (selumetinib)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: MPNST, NF1 | Phase 2 | Status: NOT_YET_RECRUITING